Company: NDRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001654954-25-005770
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 (104,474,429)  (103,438,099)Total Stockholders’ Equity  1,752,885   2,560,366 Total Liabilities and Stockholders’ Equity $3,170,598  $4,452,362 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 3Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

  Three Months Ended   Three Months Ended    March 31,  March 31,   2025  2024 Operating Expenses      Research and development $528,685  $1,041,526 Sales and marketing  68,991   238,660 General and administrative  871,606   1,500,355 Total operating expenses  1,469,282   2,780,541          Operating loss  (1,469,282)  (2,780,541)         Other Expenses        Other income (expense)  24,390   4,841 Changes in fair value of warrant liability  408,562   - Total other expenses  432,952   4,841          Loss from operations before income taxes  (1,036,330)  (2,775,700)         Provision for income taxes  -   -          Net Loss $(1,036,330) $(2,775,700)         Net loss per share – basic and diluted $(1.86) $(449.58)         Weighted average common shares – basic and diluted  557,582   6,174 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 4Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

Three Months Ended March 31, 2024  Series A Convertible  Series B Convertible       Additional      Total    Preferred Stock  Preferred Stock  Common stock  Paid in   Stock   Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Capital  Pay